105 related articles for article (PubMed ID: 22850270)
1. Comparative proteome analysis of acute myeloid leukemia with and without maturation.
Luczak M; Kaźmierczak M; Handschuh L; Lewandowski K; Komarnicki M; Figlerowicz M
J Proteomics; 2012 Oct; 75(18):5734-48. PubMed ID: 22850270
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of childhood de novo acute myeloid leukemia and myelodysplastic syndrome/AML: correlation to molecular and cytogenetic analyses.
Braoudaki M; Tzortzatou-Stathopoulou F; Anagnostopoulos AK; Papathanassiou C; Vougas K; Karamolegou K; Tsangaris GT
Amino Acids; 2011 Mar; 40(3):943-51. PubMed ID: 20711619
[TBL] [Abstract][Full Text] [Related]
3. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of proteomics between acute myeloid leukemia and acute lymphoid leukemia].
Xiao P; Zeng YY; Nie YF; Lin W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1353-6. PubMed ID: 22169282
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization.
Klaus M; Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
Cancer Genet Cytogenet; 2004 Nov; 155(1):47-56. PubMed ID: 15527902
[TBL] [Abstract][Full Text] [Related]
6. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
[TBL] [Abstract][Full Text] [Related]
7. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H
Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246
[TBL] [Abstract][Full Text] [Related]
8. [Proteomics analysis of bone marrow cells of acute myeloid leukemia M2a and prognostic significance thereof].
Tian S; Meng FY; Tang JM
Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(8):538-41. PubMed ID: 17459203
[TBL] [Abstract][Full Text] [Related]
9. [The immunophenotypic and clinical characteristics of NPM1 mutated acute myeloid leukemia patients].
Liu YR; Chang Y; Ruan GR; Qin YZ; Lai YY; Shi HX; Wang YZ; Li LD; Jiang B; Li JL
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):98-103. PubMed ID: 23611213
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets.
López-Pedrera C; Villalba JM; Siendones E; Barbarroja N; Gómez-Díaz C; Rodríguez-Ariza A; Buendía P; Torres A; Velasco F
Proteomics; 2006 Apr; 6 Suppl 1():S293-9. PubMed ID: 16521150
[TBL] [Abstract][Full Text] [Related]
11. Esterase D and gamma 1 actin level might predict results of induction therapy in patients with acute myeloid leukemia without and with maturation.
Kaźmierczak M; Luczak M; Lewandowski K; Handschuh L; Czyż A; Jarmuż M; Gniot M; Michalak M; Figlerowicz M; Komarnicki M
Med Oncol; 2013 Dec; 30(4):725. PubMed ID: 24085543
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis of human acute leukemia cells: insight into their classification.
Cui JW; Wang J; He K; Jin BF; Wang HX; Li W; Kang LH; Hu MR; Li HY; Yu M; Shen BF; Wang GJ; Zhang XM
Clin Cancer Res; 2004 Oct; 10(20):6887-96. PubMed ID: 15501966
[TBL] [Abstract][Full Text] [Related]
13. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
[TBL] [Abstract][Full Text] [Related]
14. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia.
Kwak JY; Ma TZ; Yoo MJ; Choi BH; Kim HG; Kim SR; Yim CY; Kwak YG
Exp Hematol; 2004 Sep; 32(9):836-42. PubMed ID: 15345285
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.
Corbacioglu A; Scholl C; Schlenk RF; Eiwen K; Du J; Bullinger L; Fröhling S; Reimer P; Rummel M; Derigs HG; Nachbaur D; Krauter J; Ganser A; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(23):3724-9. PubMed ID: 20625124
[TBL] [Abstract][Full Text] [Related]
16. Serum proteomic spectral characteristics of acute myeloid leukemia and their clinical significance.
Zheng RJ; Wu RJ; Ma XD
Genet Mol Res; 2017 Apr; 16(2):. PubMed ID: 28407176
[TBL] [Abstract][Full Text] [Related]
17. Perspectives of proteomics in acute myeloid leukemia.
Czibere A; Grall F; Aivado M
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1663-75. PubMed ID: 17134369
[TBL] [Abstract][Full Text] [Related]
18. Screening for methylation-silenced genes in acute myeloid leukemia HL-60 cell line by a quantitative proteomic approach.
Tang C; Tan T; Xiao Y; Ruan L; Li C; Peng F; Li M; Zhang P; Yi H; Xiao Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 35(7):641-8. PubMed ID: 20693703
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of acute myeloid leukemia and system Coulter VCS.
Bruno A; Del Poeta G; Venditti A; Stasi R; Adorno G; Aronica G; Suppo G; Di Rienzo AM; Iazzoni R; Tribalto M
Haematologica; 1994; 79(5):420-8. PubMed ID: 7843628
[TBL] [Abstract][Full Text] [Related]
20. Comparative proteomic analysis of patients with acute myeloid leukemia before and after induction therapy.
Restrepo-Rodríguez L; Prada-Arismendy J; Castillo E; Rothlisberger S
Cancer Biomark; 2023; 37(4):227-235. PubMed ID: 37302023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
